Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

425 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Course of platelet miRNAs after cessation of P2Y12 antagonists.
Jäger B, Stojkovic S, Haller PM, Piackova E, Kahl BS, Andric T, Vargas KG, Wojta J, Huber K. Jäger B, et al. Among authors: kahl bs. Eur J Clin Invest. 2019 Aug;49(8):e13149. doi: 10.1111/eci.13149. Epub 2019 Jun 23. Eur J Clin Invest. 2019. PMID: 31172515
SARS-CoV-2 Associated Pediatric Inflammatory Multisystem Syndrome With a High Prevalence of Myocarditis - A Multicenter Evaluation of Clinical and Laboratory Characteristics, Treatment and Outcome.
Thom K, Kahl B, Wagner T, van Egmond-Fröhlich A, Krainz M, Frischer T, Leeb I, Schuster C, Ehringer-Schetitska D, Minkov M, Male C, Michel-Behnke I. Thom K, et al. Among authors: kahl b. Front Pediatr. 2022 Jun 10;10:896252. doi: 10.3389/fped.2022.896252. eCollection 2022. Front Pediatr. 2022. PMID: 35757128 Free PMC article.
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas.
Foley N, Riedell PA, Bartlett NL, Cashen AF, Kahl BS, Fehniger TA, Fischer A, Moreno C, Liu J, Carson KR, Mehta-Shah N. Foley N, et al. Among authors: kahl bs. Clin Lymphoma Myeloma Leuk. 2024 Dec 4:S2152-2650(24)02436-4. doi: 10.1016/j.clml.2024.11.015. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39725584
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial.
Friedberg JW, Brady MT, Strawderman M, Kahl BS, Lossos IS, Cohen JB, Reagan PM, Casulo C, Averill BL, Baran A, Sutamtewagul G, Barr PM, Leonard JP, Ashton JM, Strang JG, Vega F, Peterson DR, Nastoupil LJ. Friedberg JW, et al. Among authors: kahl bs. EClinicalMedicine. 2024 Nov 27;78:102959. doi: 10.1016/j.eclinm.2024.102959. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39677358 Free PMC article.
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Šimkovič M, Österborg A, Laurenti L, Walker PA, Opat SS, Ciepluch H, Greil R, Hanna M, Tani M, Trněný M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, de Guibert S, Tumyan G, Laribi K, García-Marco JA, Li JY, Tian T, Liu Y, Korolkiewicz R, Szeto A, Tam CS, Jurczak W. Shadman M, et al. Among authors: kahl bs. J Clin Oncol. 2024 Dec 8:JCO2402265. doi: 10.1200/JCO-24-02265. Online ahead of print. J Clin Oncol. 2024. PMID: 39647999
425 results